Myc Proto-Oncogene Protein (MYC) Antibody (FITC)

Background

The MYC proto-oncogene encodes a basic helix-loop-helix (bHLH) transcription factor that is central to regulating cell growth, proliferation, and metabolism. It acts as a master regulator by binding to E-box sequences within the genome to control the transcription of numerous genes involved in key cellular processes, such as ribosome biogenesis, cell cycle progression, and apoptosis. Dysregulation of MYC, often through overexpression or amplification, is a hallmark of many cancers, including Burkitt lymphoma and various solid tumors. This dysregulation promotes uncontrolled cell proliferation and impairs apoptosis, contributing to tumorigenesis. Additionally, MYC interacts with multiple co-factors and chromatin-modifying complexes, further amplifying its impact on the epigenetic landscape. Given its critical role in oncogenesis, MYC is extensively studied as a therapeutic target, with ongoing efforts to develop strategies to inhibit its activity or downstream pathways to treat MYC-driven malignancies. Its widespread effects on cellular physiology underscore its importance in both normal development and disease.